Skip to main content

借助我们创新的酶促平台,我们逐步改变了可持续抗生素和他汀类药物的生产规则。

在技​​术进步方面,我们在Centrient Pharmaceuticals不断前进。通过数十年的药物创新,我们通过不断推进更安全,更可持续的制造流程为我们的行业做出了重大贡献。

我们专有的PureActives®技术就是其中一项创新。这款革命性的酶促平台于2012年首次推出,以更高效,更自然的工艺取代了我们抗生素的传统13步生产工艺。结果是简化了的过程,需要更少的能源和水,并且避免使用有害的溶剂和其他化学物质。

我们共同使用PureActives®名称使用这种绿色技术推销生产的活性药物成分(API)和最终剂型(FDF)。除了向健康和环境迈进之外,我们的创新产品组合还为客户提供了许多产品性能优势:从更高的纯度和整体质量到更长的保质期以及降低的投入成本。

因此,无论您要寻找的是质量,可靠性还是可持续性,我们的PureActives®系列都能满足您的需求。

When it comes to technological advancement, at Centrient Pharmaceuticals we are constantly moving forward. Through decades of pharmaceuticals innovation, we have made a significant contribution to our industry by continuously advancing safer and more sustainable manufacturing processes.

One such innovation is our proprietary PureActives® technology. First introduced in 2012, this revolutionary enzymatic platform replaces the traditional 13-step production process for our antibiotics with more efficient, natural processes. The result is a simplified process that requires less energy and water, and avoids the use of harmful solvents and other chemicals.

We collectively market the active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) we manufacture using this green technology under the PureActives® name. As well as a step forward for health and the environment, our innovative portfolio delivers customers a number of product performance benefits: from higher purity and overall quality to a longer shelf life and reduced input costs.

So, whether it’s Quality, Reliability or Sustainability you are looking for, our PureActives® range meets your needs head on.